MBX Biosciences(MBX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MBX MBX Biosciences

休市中 06-18 16:00:00 EDT

43.03

+1.44

+3.46%

盘后43.03

+0.000.00%

18:28 EDT

最高43.49	最低40.77	成交量83.22万
今开42.84	昨收41.59	日振幅6.55%
总市值20.44亿	流通市值11.07亿	总股本4,751万
成交额3,522万	换手率3.24%	流通股本2,572万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":43.03,"timestamp":1781812800000,"preClose":41.59,"halted":0,"volume":832153,"hourTrading":{"tag":"盘后","latestPrice":43.03,"preClose":43.03,"latestTime":"18:28 EDT","volume":40125,"amount":1726553.356,"timestamp":1781821704333,"change":0,"changeRate":0,"amplitude":0.004416},"delay":0,"changeRate":0.03462370762202447,"floatShares":25718200,"shares":47510200,"eps":-2.186143,"marketStatus":"休市中","change":1.44,"latestTime":"06-18 16:00:00 EDT","open":42.84,"high":43.49,"low":40.765,"amount":35215691.41181,"amplitude":0.065521,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.186143,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":41.59,"preHourTrading":{"tag":"盘前","latestPrice":42.53,"preClose":41.59,"latestTime":"09:28 EDT","volume":272,"amount":11324.249440000001,"timestamp":1781789281008,"change":0.94,"changeRate":0.022602,"amplitude":0.030777},"postHourTrading":{"tag":"盘后","latestPrice":43.03,"preClose":43.03,"latestTime":"18:28 EDT","volume":40125,"amount":1726553.356,"timestamp":1781821704333,"change":0,"changeRate":0,"amplitude":0.004416},"volumeRatio":0.5220905025680955,"impliedVol":1.0586,"impliedVolPercentile":0.5817},"requestUrl":"/m/hq/s/MBX","defaultTab":"news","newsList":[{"id":"1169083837","title":"MBX核心药物试验结果符合预期，但部分投资者或期待更高——市场观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1169083837","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169083837?lang=zh_cn&edition=full","pubTime":"2026-06-13 01:22","pubTimestamp":1781284950,"startTime":"0","endTime":"0","summary":"MBX Biosciences公布了其用于治疗甲状旁腺功能减退症的药物canvuparatide的二期试验结果，随后股价下跌5.5%。瑞穗银行的分析指出，该药物在52周时达到了57%的综合应答率，这是衡量治疗成功的关键指标，与其竞争对手Yorvipath的64%水平相当。然而，分析人士认为，部分投资者可能会提出异议，因为在与患者使用相关的更宽松标准下，Yorvipath的实际基准应答率可能高达80%。尽管如此，分析师们对此次试验结果以及canvuparatide每周一次的给药方案仍持乐观态度。该方案可将注射次数减少86%，他们表示，这“继续支持canvuparatide的商业潜力”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ISBC","LU0109394709.USD","BK4139","LU0320765992.SGD","BK4007","MBX","LU0889565916.HKD","BK4585","ASND","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160063733","title":"异动解读 | MBX Biosciences公布肥胖症产品管线进展，股价盘中大涨5.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160063733","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160063733?lang=zh_cn&edition=full","pubTime":"2026-05-11 22:49","pubTimestamp":1778510954,"startTime":"0","endTime":"0","summary":"MBX Biosciences今日盘中大涨5.92%，引起了市场的广泛关注。消息面上，MBX Biosciences近日公布了其肥胖症产品管线的更新信息，其中包含了其候选药物MBX 4291的初步一期临床试验数据。这些早期数据为该药物实现每月仅需给药一次的潜力提供了初步支持，表明公司在药物开发方面取得了积极进展。这一进展可能增强了投资者对公司未来前景的信心，从而推动了股价的上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177582062","title":"MBX Biosciences公布肥胖症产品管线进展，包括MBX 4291初步一期数据支持每月一次给药潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1177582062","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177582062?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:01","pubTimestamp":1778497285,"startTime":"0","endTime":"0","summary":"MBX Biosciences 近日公布了其肥胖症产品管线的更新信息，其中包含了其候选药物 MBX 4291 的初步一期临床试验数据。这些早期数据为该药物实现每月仅需给药一次的潜力提供了初步支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195457870","title":"MBX Biosciences宣布成功完成第二阶段FDA会议，并公布每周一次Canvuparatide治疗甲状旁腺功能减退症的第三阶段开发计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1195457870","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195457870?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:01","pubTimestamp":1773057698,"startTime":"0","endTime":"0","summary":"MBX Biosciences已成功完成第二阶段末期与美国食品药品监督管理局（FDA）的会议，并正式公布了针对甲状旁腺功能减退症的创新疗法——每周一次Canvuparatide的第三阶段临床开发计划。此次会议的顺利结束标志着该药物在研发进程中迈出了关键一步，为后续的大规模临床试验奠定了坚实基础。\n公司详细阐述了第三阶段的研究策略，重点聚焦于验证Canvuparatide的长期疗效与安全性。这一每周给药方案有望极大提升患者依从性，为甲状旁腺功能减退症治疗领域带来新的突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184880172","title":"MBX Biosciences将在第44届摩根大通医疗健康年会公布2026年展望及业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1184880172","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184880172?lang=zh_cn&edition=full","pubTime":"2026-01-12 05:01","pubTimestamp":1768165309,"startTime":"0","endTime":"0","summary":"MBX Biosciences宣布将参与第44届摩根大通年度医疗健康大会，届时将首次披露公司对2026年的战略展望及最新业务动态。此次亮相将为投资者提供深入了解公司研发管线推进、商业化布局及长期发展路径的重要窗口。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601350498","title":"Mbx Biosciences, Inc.盘中异动 早盘股价大涨5.00%报30.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601350498","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601350498?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:31","pubTimestamp":1767796293,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日22时31分，Mbx Biosciences, Inc.股票出现波动，股价大幅拉升5.00%。截至发稿，该股报30.14美元/股，成交量1.3189万股，换手率0.03%，振幅0.82%。Mbx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。Mbx Biosciences, Inc.公司简介：MBX Biosciences Inc是一家临床阶段的生物制药公司，专注于发现和开发用于治疗内分泌和代谢紊乱的新型精确肽疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010722313497a132d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010722313497a132d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","BK4585","BK4533","IE00BLSP4239.USD","LU1244550221.USD","LU1162221912.USD","PEP","LU0320765646.SGD","BK4504","LU0098860793.USD","BK4566","MBX","LU1894683264.USD","BK4177","IE00BN8TJ469.HKD","LU1894683348.USD","BK4550","IE00BLSP4452.SGD","BK4588","BK4581","LU1929549753.HKD","BK4007","IE00BBT3K403.USD","IE00B3T34201.USD","LU0234572021.USD","LU1244550577.SGD","LU1244550494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600922740","title":"Mbx Biosciences, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600922740","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600922740?lang=zh_cn&edition=full","pubTime":"2026-01-03 00:01","pubTimestamp":1767369688,"startTime":"0","endTime":"0","summary":"北京时间2026年01月03日00时01分，Mbx Biosciences, Inc.股票出现异动，股价大幅下跌5.01%。Mbx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.54%。Mbx Biosciences, Inc.公司简介：MBX Biosciences Inc是一家临床阶段的生物制药公司，专注于发现和开发用于治疗内分泌和代谢紊乱的新型精确肽疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010300012897a0f451&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010300012897a0f451&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1244550577.SGD","IE00BN8TJ469.HKD","LU0320765646.SGD","LU1162221912.USD","BK4585","PEP","IE00B3T34201.USD","BK4177","BK4007","LU1929549753.HKD","MBX","BK4566","LU0098860793.USD","LU1894683264.USD","LU1894683348.USD","BK4534","BK4533","BK4581","BK4588","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU1244550221.USD","LU1244550494.USD","BK4504","LU0234572021.USD","IE00BBT3K403.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592135176","title":"Mbx Biosciences, Inc.盘中异动 下午盘大幅拉升5.02%报29.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592135176","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592135176?lang=zh_cn&edition=full","pubTime":"2025-12-19 04:26","pubTimestamp":1766089562,"startTime":"0","endTime":"0","summary":"北京时间2025年12月19日04时26分，Mbx Biosciences, Inc.股票出现波动，股价急速拉升5.02%。截至发稿，该股报29.09美元/股，成交量83.3754万股，换手率1.86%，振幅4.55%。Mbx Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.53%。Mbx Biosciences, Inc.公司简介：MBX Biosciences Inc是一家临床阶段的生物制药公司，专注于发现和开发用于治疗内分泌和代谢紊乱的新型精确肽疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219042602a6b3dbc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219042602a6b3dbc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1244550577.SGD","LU0320765646.SGD","BK4581","BK4550","IE00B3T34201.USD","LU1894683264.USD","LU1894683348.USD","BK4177","LU1929549753.HKD","BK4585","IE00BLSP4452.SGD","BK4588","BK4007","BK4566","BK4504","IE00BLSP4239.USD","PEP","BK4533","BK4534","MBX","IE00BN8TJ469.HKD","LU0098860793.USD","LU1162221912.USD","IE00BBT3K403.USD","LU1244550221.USD","LU1244550494.USD","LU0234572021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2482177892","title":"莱尔德热系统宣布推出用于下一代光电设备的全新微型热电制冷器产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2482177892","media":"赛迪网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482177892?lang=zh_cn&edition=full","pubTime":"2024-11-12 17:18","pubTimestamp":1731403118,"startTime":"0","endTime":"0","summary":"莱尔德热系统宣布扩展微型热电制冷器产品线，并推出OptoTEC MBX系列，该系列适用于空间受限的高性能光电应用。MBX系列具有高达43 W/cm2的高热泵密度，在50℃环境温度下可实现高达82℃温差。MBX系列可依照客户要求进行客制化设计，满足特定的外形尺寸、热泵密度和制冷效率等要求。莱尔德热系统还可提供多种特殊的表面处理选项，包括镀金图案、热敏电阻附件和密封，以适应那些非密封设备。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112172506abb98c2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112172506abb98c2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0124384867.USD","BK4585","LU1978683503.SGD","IR","LU0256863811.USD","BK4588","MBX","SG9999001440.SGD","BK4161","LU0417517546.SGD","LU0256863902.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154740936","title":"异动解读 | MBX生物科学上市同日大涨53% 投资者看好其减肥新药前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1154740936","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154740936?lang=zh_cn&edition=full","pubTime":"2024-09-14 11:06","pubTimestamp":1726283190,"startTime":"0","endTime":"0","summary":"MBX生物科学公司在纳斯达克上市首日即大获成功,股价大涨53.25%,收于23.65美元,引发市场广泛关注。该公司聚焦内分泌和代谢疾病的创新治疗,正在开发一系列候选药物以应对糖尿病、肥胖等常见疾病,上市股价表现耀眼反映了投资者对公司前景的高度认可。MBX生物科学最值得关注的是其肥胖候选药物MBX 4291,这一长效创新疗法有望成为新一代高效减肥药。未来若候选药物顺利商业化,MBX生物科学将捕获可观的发展机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2467867056","title":"生物医药公司MBX纳斯达克上市：大涨48% 公司市值7亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467867056","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467867056?lang=zh_cn&edition=full","pubTime":"2024-09-14 11:04","pubTimestamp":1726283096,"startTime":"0","endTime":"0","summary":"生物医药公司MBX Biosciences（股票代码：“MBX”）昨日在美国纳斯达克上市。MBX Biosciences发行价为16美元，发行1020万股，募资总额为1.63亿美元。MBX Biosciences开盘价为23美元，较发行价上涨44%；收盘价为23.65美元，较发行价上涨47.81%；以收盘价计算，公司市值为7.13亿美元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240914/6386190868877293219063255.png","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240914/6386190868877293219063255.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n27758/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK1147","MNQmain","03086","PSQ",".IXIC","TQQQ","NQmain","ARTL","QID","MBX","SQQQ","QLD","BK4007"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1159152248","title":"异动解读 | 研发减肥新药 MBX生物科学上市首日大涨44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159152248","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159152248?lang=zh_cn&edition=full","pubTime":"2024-09-14 00:38","pubTimestamp":1726245495,"startTime":"0","endTime":"0","summary":"MBX生物科学公司(MBX Biosciences)周五在纳斯达克上市首日即大获成功,股票大涨43.88%,收于20.11美元。\n\nMBX生物科学是一家新兴的生物制药公司,正专注于开发针对内分泌和代谢紊乱的疗法,包括糖尿病和肥胖症等常见疾病。公司研发管线中有多个候选药物品种,预期将有助于调节体内胰岛素等重要激素的水平,从而改善患者的症状。\n\n分析人士认为,MBX生物科学在上市首日股价大涨,反映了市场投资者对该公司减肥新药以及整体业务前景的看好。近年来,糖尿病和肥胖人群不断增加,减肥新药需求旺盛,为这家新兴生物科技公司提供了广阔的市场发展空间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mbxbio.com","stockEarnings":[{"period":"1week","weight":0.1552},{"period":"1month","weight":0.4159},{"period":"3month","weight":0.5003},{"period":"6month","weight":0.4145},{"period":"1year","weight":3.1858},{"period":"ytd","weight":0.3643}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MBX Biosciences, Inc.于2018年8月作为印第安纳州有限责任公司成立，并于2019年4月转变为特拉华州公司。该公司是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于内分泌及代谢疾病的新型精准肽疗法。其研发管线包括用于甲状旁腺功能减退、肥胖症和减肥后低血糖症的候选药物，这些药物是利用其专有的精准内分泌肽平台设计的。","exchange":"NASDAQ","name":"MBX Biosciences","nameEN":"MBX Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MBX Biosciences(MBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MBX Biosciences(MBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MBX Biosciences,MBX,MBX Biosciences股票,MBX Biosciences股票老虎,MBX Biosciences股票老虎国际,MBX Biosciences行情,MBX Biosciences股票行情,MBX Biosciences股价,MBX Biosciences股市,MBX Biosciences股票价格,MBX Biosciences股票交易,MBX Biosciences股票购买,MBX Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MBX Biosciences(MBX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MBX Biosciences(MBX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}